Tag Archives: Emerging Markets

Why all the negativity around National Health Insurance in South Africa?

23 Aug
National-Health-Insurance

Why all the negativity around national health insurance (NHI) in South Africa? There is so much bad news such as comments by the Solidarity Research Institute that NHI will collapse the healthcare system, the Free Market Foundation believes the NHI will be a gateway for corruption, and Alex van den Heever at Wits University thinks […]

Market Access Landscape in the Middle East:The Next Five Years

06 Jun
Middle-East

The market access landscape in the Middle East is changing rapidly. The growth of private health insurance markets in the Gulf is a significant catalyst for the re-organisation of private sector stakeholders and improvements in internal reimbursement policies. In the past, Payors were relatively generous in their reimbursement of new technologies, but in the next […]

Is Real-World Evidence all it’s trumped-up to be?

10 Apr
multiplechro

There’s so much discussion around Big Data and Real-World Evidence (RWE) in improving access to medicines. RWE is clinical data collected after the publication of clinical trials used for marketing authorization. Sources may include health insurance claims databases, patient registries, hospital patient records, among others. Clinical trials are by design the gold standard for new […]

C&C at ISPOR in Glasgow

11 Oct
ISPOR

C&C at ISPOR in Glasgow C&C will be at ISPOR Glasgow in just a few weeks. Will you? We’re presenting results of our recent work for Clients in Sub-Saharan Africa and the Middle East. We put great effort into analysing new health technologies, determining their budget impact in various markets, and assessing market access opportunities. […]

WHO’s serious reservations on Value-Based Pricing: Conflicts and Nuances

08 Jun
WHO Fair Pricing Forum Carapinha & Company

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

The Globalization of NICE’s Health Technology Appraisals

01 May
NICE-Small

The National Institute for Health and Care Excellence (NICE) in England often comes up in conversations on medicine reimbursement. The sequence of events goes something like this: a new medicine is planned for launch in a growth market (mostly middle-income countries), but the government and private health insurance companies are uncertain of its economic and […]

En garde QALY! Is your end nigh?

05 Apr
qalys

The Spanish Ministry of Health recently rejected the use of QALYs in cost-effectiveness analyses. At issue is the subjective nature of the parameters used to develop the QALY. The Quality-Adjusted Life-Years (QALY) is a product of the change in utilities associated with a treatment multiplied by the time of treatment exposure. The QALYs gained combined […]

Comment on the implications of external price referencing of pharmaceuticals in Middle East countries

15 Aug

Expert Review of Pharmacoeconomics & Outcomes Research Corresponding Author: Dr. João L. Carapinha, Ph.D External Price Referencing (EPR) is frequently used by countries to control pharmaceutical prices but studies to substantiate its use in the Middle East (ME) is lacking. The paper by Kalo et al set-out to fill this lacuna through three objectives: i) […]

What makes a good systematic review and meta-analysis?

15 Aug

Webinar: What makes a good systematic review and meta-analysis? 13 September 2016 @ 7:30am Boston (12:30pm London, 1:30pm Johannesburg. 3:30pm Dubai) Here, we’ll cover the nuts and bolts of what we look for in a high-quality, systematic review and meta-analysis, beginning with a focused research question that helps the reader understand why we need this […]

Carapinha Logo